Sanofi: Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)

Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)

Q3 2021 sales grew double digit to €10.4 billion (up 10.1%) due to strong growth from Dupixent®, Vaccines and CHC

Specialty Care deals increased20.2 with strong donation from Dupixent ® (54.6 to€ million)
.Vaccines up16.5, with record daily deals driven by discerned flu vaccines and meningitis ballot recovery
. CHC increased11.1 driven by growth of Pain care and Digestive Wellness orders
General Medicines deals down1.7 while metamorphosis of business model supports core means growth (up4.5)
Q3 2021 business EPS (2) growth of19.1 at CER driven by deals performance and edge

Business EPS (2) was€2.18, up19.1 on a reported base
BOI periphery reached34.1 up2.2 ppts reflecting enhancement in Gross periphery and continued expenditure operation
IFRS EPS was€1.85 (up19.4)

Progress on Commercial Social Responsibility strategy

Carbon impartiality target accelerated to 2030; a 2050 net zero objective established
Sanofi ranked# 1 in the European pharma sector by ESG standing agency Vigeo Eiris ( part of Moody’s ESG Results)
Crucial corner and nonsupervisory achievements on R&D metamorphosis

Positive vital phase 3 readouts for Dupixent ® in habitual robotic urticaria and child atopic dermatitis (6 months to 5 times)
Nexviazyme ® blessings inU.S. and Japan
Cessions of sutimlimab in theU.S. and olipudase alfa in Japan under the Sakigake pathway
Acquisition of Translate Bio completed, first positive clinical data read-out validating the mRNA platform
. Full- time 2021 business EPS guidance revised overhead (1)

Sanofi now expects 2021 business EPS (2) to grow around 14 at CER (3), barring unlooked-for major adverse events. Applying average October 2021 exchange rates, the currency impact on 2021 business EPS is estimated to be between-3.5 to-4.5
Sanofi Chief Executive Officer, Paul Hudson, reflected
.“ Sanofi has delivered outstanding fiscal results in the third quarter. Double- number deals growth in the period was driven by the remarkable performance of Dupixent ®, record deals of Vaccines and business instigation in Consumer Healthcare, all in line with our strategic precedences. As a result of our deals performance and strong earnings, we’ve upgraded our full- time EPS guidance growth to around 14 at CER. In R&D, our growing channel of potentially transformative curatives has progressed, including the most recent positive readouts for Dupixent ® in Eosinophilic esophagitis and Prurigo nodularis as well as theU.S. blessing and launch of Nexviazyme ® in Pompe complaint. With advanced R&D investment behind our channel means and the two targeted bolt-on accessions of Translate Bio and Kadmon, we’ve further increased our commitment to bring innovative drugs to cases and drive unborn growth. Aligned with our contract with society and leading up to Bobby 26, we’ve set ourselves new ambitious ESG targets to reduce carbon emigrations and accelerate our conduct in fighting global climate change.”

Q3 2021 Change Change
at CER 9M 2021 Change Change
at CER
IFRS net deals reported€ m10.110.1€ m4.28.2
IFRS net income reported (4)€ m18.7,€ m-54.7 —
IFRS EPS reported€1.8519.4,€4.07-54.6 —
Free cash inflow (5)€ m16.9,€ m1.9 —
Business operating income€ m17.5€ m9.715.0
Business net income (2)€ m19.018.8€ m11.416.9
Business EPS (2)€2.1819.119.1€5.1811.617.2
Changes in net deals are expressed at constant exchange rates (CER) unless else indicated ( description in Excursus 7)

(1) Sanofi formerly raised its full- time 2021 business EPS growth guidance to around 12 at CER on July 29; (2) In order to grease an understanding of functional performance, Sanofi comments on the business net income statement. Business net income is anon-GAAP fiscal measure ( description in Excursus 7). The consolidated income statement for Q3 2021 is handed in Excursus 3 and a conciliation of reported IFRS net income to business net income is set forth in Excursus 4; (3) 2020 paraphrased business EPS was€5.86; (4) 9M 2021 IFRS net income reported reflected capital gain from deals of Regeneron shares in Q2 2020; (5) Free cash inflow is anon-GAAP fiscal measure ( description in Excursus 7)
2021 third- quarter and first nine months Sanofi deals


Unless else indicated, all chance changes in deals in this press release are stated at CER1
.—————————-

In the third quarter of 2021, Sanofi deals were€ million, up10.1 on a reported base. Exchange rate movements had a neutral effect, the negative impact of theU.S. bone, Japanese yearning and Turkish lira was neutralize by the increase of the Chinese Yuan and some other currencies.
In the first nine months Sanofi deals reached€ million, over4.2 on a reported base. Exchange rate movements had a negative effect of4.0 chance points. At CER, company deals were over8.2.

About Sanofi
Sanofi is devoted to supporting people through their health challenges. We’re a global biopharmaceutical company concentrated on mortal health. We help illness with vaccines, give innovative treatments to fight pain and ease suffering. We stand by the many who suffer from rare conditions and the millions with long- term habitual conditions.

With further than people in 100 countries, Sanofi is transubstantiating scientific invention into healthcare results around the globe.

Source link: https://www.sanofi.com/